|Articles|March 23, 2017
Medidata Platform Selected for Leukemia Trial
Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML).
Advertisement
Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML). Medidata is also incorporating its EDC, management and reporting solution, Medidata Rave, and its medical coding solution, Medidata Coder, to this trial.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility
2
Achieving Clinical Trial Success with Three Key Elements of eCOA User Acceptance Testing
3
Tapping the Global Potential of China’s Biotech Surge
4
2026 DIA Global Annual Meeting: How Structured Protocols Enable Automated Amendments and Real-Time FDA Oversight
5